AI-Based Screening for Lymph Node Metastasis Across Multiple Cancer Types
- Valeryia Ladutska
- Apr 30
- 1 min read
Singapore, April 30, 2025 — Qritive participated in the 114th USCAP Annual Meeting with studies highlighting the value of AI-powered tools in improving diagnostic accuracy and efficiency across various pathology workflows.
A Comprehensive Study for Evaluation of a Deep Learning Algorithm to Identify Lymph Node Metastasis
USCAP 114th Annual Meeting | March 22–27, 2025 | Boston, Massachusetts
This study presents the development and evaluation of a deep learning algorithm designed to support the detection of lymph node metastasis in breast, colon, gastric, and other carcinoma cases.
By integrating AI into pathology workflows, the study demonstrates the potential to enhance diagnostic efficiency, reduce turnaround times, and provide consistent results across a variety of cancer types. The algorithm also offers visual outputs to assist pathologists in confirming metastatic findings with greater confidence.
About Qritive
Qritive, headquartered in Singapore with operations in the US and India, is transforming digital pathology through advanced AI-powered solutions that support cancer diagnosis and improve health outcomes.
By leveraging cutting-edge deep learning technology, Qritive supports pathologists in the interpretation of pathology assessments and enhances pathology workflows—enabling faster, more accurate diagnoses and reducing time to treatment.
Qritive is committed to empowering healthcare professionals around the world with tools that promote collaboration and high performance, regardless of complexity or distance.
Get in Touch
Want to learn more about our solutions or explore potential collaborations?
Visit www.qritive.com or contact us at info@qritive.com
